Novo Nordisk's Daring Success

Any drugmaker bold enough to test one of its drug candidates directly against a competitor dramatically increases that compound's risk of failure. On Friday, Novo Nordisk (NYSE: NVO  ) seems to have cleared this lofty hurdle, delivering promising results for a potential blockbuster diabetes compound.

Testing a drug in development against an already approved competitor is always tougher than a traditional placebo-controlled study. Not only must the compound show that it is effective and relatively safe, but it must also prove itself at least as effective as the rival drug. Novo Nordisk tested its type 2 diabetes GLP-1 analogue treatment liraglutide in a phase 3 study against Eli Lilly (NYSE: LLY  ) and Amylin Pharmaceuticals' (Nasdaq: AMLN  ) already-approved GLP-1 analogue Byetta.

Patients treated with liraglutide saw their blood sugar levels reduced by "more than 1.1 percentage points" with liraglutide, versus "less than 0.8 percentage points" with Byetta. This is the most commonly used efficacy endpoint in any diabetes study, and the gold standard used in evaluating such treatments by the FDA and other medical authorities worldwide.

Although I'm not calling this anything close to definitive yet, liraglutide also appears to have bested Byetta on safety issues common to the two drugs, including nausea and minor hypoglycemia. In addition, diabetics only need to inject themselves with liraglutide once a day, compared to Byetta's twice-a-day dosing. Assuming that Novo Nordisk's study was well-balanced, it looks like liraglutide trounced Byetta across the board on efficacy, convenience, and possibly safety.

Lilly and Amylin do have a long-acting once-a-week version of Byetta, designed using Alkermes' (Nasdaq: ALKS  ) extended-release technology, but it won't be submitted to the FDA until next year. Other drugmakers like MannKind (Nasdaq: MNKD  ) have also done work on developing rival GLP-1 analogues. That said, this space now seems like Novo's to lose, if liraglutide can get onto the market. These promising results provide yet another reason to like Novo Nordisk.

More Foolishness to get your blood sugar up:

MannKind is an active Hidden Gems Pay Dirt pick. Eli Lilly is a selection of the Income Investor newsletter. Whether you like your companies big or small, dividend-laden or with "multibagger" written all over them, we've got a newsletter for you.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 661123, ~/Articles/ArticleHandler.aspx, 12/19/2014 3:56:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 17,778.15 421.28 2.43%
S&P 500 2,061.23 48.34 2.40%
NASD 4,748.40 104.08 2.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/18/2014 4:02 PM
NVO $44.40 Up +0.82 +1.88%
Novo Nordisk CAPS Rating: *****
ALKS $57.68 Up +1.77 +3.17%
Alkermes, Inc. CAPS Rating: ***
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
LLY $72.45 Up +2.17 +3.09%
Eli Lilly & Co. CAPS Rating: ****
MNKD $5.41 Up +0.22 +4.24%
MannKind Corp CAPS Rating: ***

Advertisement